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Abstract: 20 
Mycoplasma genitalium is frequently associated with urogenital and rectal infections, with 21 
the number of cases of macrolide resistant and quinolone resistant M. genitalium continuing 22 
to increase. In this study, we examined the levels of antibiotic resistance to these two 23 
common antibiotic treatments in geographically distinct locations in Queensland, Australia. 24 
Samples were screened for macrolide resistance-associated mutations using a commercially 25 
available kit (ResistancePlus™ MG; SpeeDx) and quinolone resistance-associated mutations 26 
were identified by PCR and DNA sequencing. Comparisons between antibiotic resistance 27 
mutations and location/gender were performed. Levels of M. genitalium macrolide resistance 28 
were high across both locations (62%). Quinolone resistance mutations were found in ~10% 29 
of all samples, with a number of samples harboring mutations conferring resistance to both 30 
macrolides and quinolones. Quinolone resistance was higher in Southeast Queensland, 31 
compared to North Queensland and this was consistent in both males and females (P = 32 
0.007). Rectal samples from males harbored high levels of macrolide (75.9%) and quinolone 33 
(19%) resistance, with 15.5% harboring resistance to both classes of antibiotics. Overall the 34 
lowest observed level of resistance was for quinolones in females from North Queensland 35 
(1.6%). These data highlight the high levels of antibiotic resistance in M. genitalium within 36 
Queensland and the challenges faced by STI clinicians in managing these infections. The data 37 
do however show that levels of antibiotic resistance may differ between populations within 38 
the same state, which has implications for clinical management and treatment guidelines. 39 
These findings also support the need for ongoing antibiotic resistance surveillance and 40 
tailored treatment. 41 
 42 
Introduction:  43 
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Mycoplasma genitalium was first identified in the urogenital tract of men in 1981 (1) and has 44 
since been confirmed as a sexually transmissible bacterium that is responsible for a range of 45 
sequelae. M. genitalium has been associated with acute and chronic urethritis in men, and can 46 
cause urethritis, cervicitis and pelvic inflammatory disease in women (2). Without 47 
appropriate treatment, M. genitalium infections are often chronic, with approximately 25% of 48 
infections persisting for >12 months, and some infections in women have been shown to 49 
persist for up to 2 years (3).  50 
 51 
More recently, M. genitalium has gained widespread attention due to its increasing resistance 52 
to antibiotic treatments and as a consequence is now listed as a major emerging issue in the 53 
STI treatment guidelines published by the United States Centre for Disease Control and 54 
Prevention (4). Unlike other antibiotic resistant STI pathogens, such as Neisseria 55 
gonorrhoeae, for which antibiotic resistance increased somewhat steadily over time, the 56 
emergence and spread of antibiotic resistant M. genitalium appears to have occurred 57 
relatively quickly, and has prompted recent changes in the Australian and UK treatment 58 
guidelines. These guidelines now all recommend a 7-day course of doxycycline as empiric 59 
therapy for M. genitalium associated syndromes, and the use of a combined diagnostic-60 
resistance assay where available to select an antibiotic to which the M. genitalium is likely to 61 
be susceptible (5). This resistance-guided approach involves the use of azithromycin for 62 
macrolide-susceptible infections or a quinolone, such as moxifloxacin or sitafloxacin, for 63 
macrolide-resistant infections to optimize cure (6, 7). However, there are still worrying trends 64 
in the levels of macrolide and quinolone resistant strains of M. genitalium that continue to 65 
threaten the efficacy of these treatment approaches.  66 
 67 
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Macrolide resistance was first reported in M. genitalium in 2008 (8), and since this time the 68 
efficacy of these antibiotic treatments have diminished, with some studies reporting treatment 69 
success as low as 40% (4). The efficacy of moxifloxacin has also begun to decline, with 70 
recent meta-analyses showing a decrease in cure rates from 100% in studies conducted prior 71 
to 2010, to 89% in studies published after 2010 (9). The resistance mechanisms that underpin 72 
M. genitalium resistance to macrolides are well documented, enabling molecular methods to 73 
be developed to readily characterize the nucleotide mutations directly within M. genitalium-74 
positive clinical samples. For macrolide resistance, five single nucleotide mutations at 75 
positions 2058 and 2059 within the macrolide resistance-determining region (MRDR) of the 76 
23S rRNA gene are each independently associated with the failure of azithromycin (8). While 77 
resistance to quinolones has been associated with various mutations in the quinolone 78 
resistance-determining regions (QRDR) of the topoisomerase gene, parC, the contribution of 79 
specific parC mutations to treatment failure is still being determined. Similarly, the role of 80 
nucleotide mutations within the QRDR of the DNA gyrase gene, gyrA, is somewhat unclear 81 
with respect to clinical treatment failure (10-14). 82 
 83 
In Australia, there have now been several studies examining M. genitalium antimicrobial 84 
resistance. In brief, these studies have shown that the current levels of macrolide resistance 85 
exceed 50% in the urban centers of Melbourne, Sydney and Brisbane (15-17) and 40% in 86 
backpacker populations in Northern Queensland (18), with sexual orientation being an 87 
important determinant of resistance, due to higher rates of antibiotic resistance in men who 88 
have sex with men (MSM) (19). Quinolone resistance, previously rare in M. genitalium in 89 
Australia, has been reported to be as high as 13.6% in a study from Melbourne in 2012 - 2013 90 
(14, 20). In this current study, we further investigated and compared rates of both macrolide 91 
and quinolone antibiotic resistance among M. genitalium obtained from two distinct regions 92 
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within Queensland: South-East Queensland (SEQ; which includes the cities of Brisbane [the 93 
capital of Queensland] and the Gold Coast) and North Queensland (NQ; including the city of 94 
Townsville, and surrounding regional and remote settings). Levels of resistance were further 95 
compared between males and females.  96 
 97 
Methods: 98 
Sample population:  99 
This study was approved by the Children’s Health Queensland human research ethics 100 
committee (HREC/12/QRCH/139). This retrospective study was performed on samples 101 
submitted to Pathology Queensland, Australia for the detection of M. genitalium by PCR 102 
between 2013 and 2017. The M. genitalium PCR utilized by Pathology Queensland was an 103 
in-house PCR method targeting the M. genitalium MgPa adhesin gene (15). Extracted DNA 104 
from M. genitalium positive samples was sent to The University of Queensland Centre for 105 
Clinical Research for screening for the presence of antibiotic resistance markers. The patients 106 
primarily comprised of those presenting to sexual health clinics with genital symptoms in 107 
whom testing for M. genitalium was indicated (e.g. urethritis, cervicitis, pelvic inflammatory 108 
disease and proctitis); Screening for M. genitalium is not currently recommended in the 109 
Australian guidelines.  Samples used within this study including urine (n = 280), 110 
cervicovaginal swabs (n = 90), urethral swabs (n = 10), anal/rectal swabs (n = 60), throat 111 
swabs (n = 1) and samples from unknown sites (n = 6). 112 
Antibiotic resistance screening: 113 
Mutations (A2058G, A2058C, A2058T, A2059G and A2059C) within the macrolide 114 
resistance determining region (MRDR) of the 23S rRNA gene were detected using a 115 
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commercially available kit (ResistancePlus™ MG Kit; SpeeDx; Sydney, Australia) (21-23). 116 
The kit is TGA-approved and CE-IVD marked, however is not currently for sale in the USA.  117 
 118 
Mutations within the QRDR of the gyrA and parC genes were detected by PCR, using 119 
previously designed primers (14), and Sanger sequencing. Briefly, the Qiagen Quantitect 120 
SYBR kit (Qiagen, Australia) was used as the basis for the PCR reaction mix, and PCR 121 
products were submitted for DNA sequencing at the Australian Genome Research Facility 122 
(AGRF; Brisbane Australia). Alterations to the nucleotide sequences within the QRDR were 123 
compared to mutations that have been previously reported to be associated with clinical 124 
treatment failure or elevated minimum inhibitory concentration (MIC) values for quinolones 125 
in M. genitalium or other Mycoplasma spp. and Ureaplasma spp. (10-14).  126 
 127 
Statistics: 128 
Comparisons across groups of categorical variables (e.g. gender, location) were performed 129 
using Pearson’s Chi-square test. Statistical significance was accepted as P < 0.05.  130 
 131 
Results:  132 
Sample population: 133 
A total of 524 M. genitalium positive samples were received from Pathology Queensland. Of 134 
these, 15 samples resulted in discordant results where we were unable to confirm the 135 
presence of M. genitalium and these were removed from our final dataset. We also identified 136 
62 samples that were considered to be either a ‘test of cure’ (a patient sampled within 3 137 
months of their initial presentation) or where a patient was sampled at multiple anatomical 138 
sites. These 62 samples were excluded from the primary analysis to determine the proportion 139 
of samples with macrolide and quinolone resistance, leaving 447 samples in the primary 140 
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analysis. Of these additional samples, 50 were included in an additional assessment 141 
investigating the temporal changes in antibiotic resistance within individual patients (n = 50), 142 
with the remaining 12 samples excluded from this secondary analysis as they were collected 143 
from multiple anatomical sites of the same patient.  144 
  145 
These 447 samples included 14 samples from 2013, 61 samples from 2016 and 374 samples 146 
from 2017, representing 176 females and 269 males, with two individuals who did not 147 
disclose their gender. Two hundred and nine samples originated from the SEQ region, while 148 
238 M. genitalium samples originated from NQ. Of these, 26 samples did not have a 149 
complete gyrA sequencing performed due to insufficient DNA however these remained 150 
within our primary analysis as mutations in this region are currently of uncertain clinical 151 
significance.  152 
 153 
MRDR and QRDR mutations identified in samples:  154 
As the ResistancePlus™ MG assay was used to detect MRDR mutations and we did not 155 
perform any DNA sequencing of the 23S rRNA gene, specific MRDR mutations were unable 156 
to be reported. However, sequencing of the QRDR of parC and gyrA was undertaken and 157 
specific quinolone resistance-associated amino acid changes were able to be reported. We 158 
observed mutations within the topoisomerase gene, parC, and only two mutations of 159 
uncertain clinical significance were observed within the DNA gyrase gene, gyrA. In 160 
summarising the most common amino acid mutations observed within the study, we grouped 161 
those mutations that were considered likely to be of clinical significance based on previous 162 
publications that correlated quinolone mutations with treatment outcomes (20) and found that 163 
the parC mutations S83I, D87Y and D87N were the most frequently observed mutations of 164 
clinical significance and this was consistent across both SEQ and NQ (Table 1). The two 165 
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gyrA mutations observed within this study were considered to be of uncertain clinical 166 
significance, as these were co-detected in M. genitalium which also harboured S83I parC 167 
mutations that are known to be associated with treatment failure (24). 168 
 169 
Proportion of samples with MRDR and QRDR mutations: 170 
Among the 447 patient samples, 277/447 (62.0%) carried strains which harboured MRDR, 171 
while a total of 47/447 (10.5%) samples harboured M. genitalium strains with parC or gyrA 172 
mutations in their QRDR. A total of 7.8% (35/447) patient samples harboured both MRDR 173 
and QRDR mutations (Table 2), herein referred to as dual class resistance. There was no 174 
evidence that the levels of MRDR or QRDR mutations changed over the study period (data 175 
not shown). 176 
 177 
Regional differences in the levels of antibiotic resistance: 178 
Both SEQ and the NQ regions of Queensland had similar proportions of samples with MRDR 179 
mutations (136/209; 65.1% and 141/238; 59.2%, respectively; P = 0.21). However, the levels 180 
of parC/gyrA mutations was significantly different between the two regions: SEQ M. 181 
genitalium samples were significantly more likely to harbour mutations associated with 182 
quinolone resistance (39/209; 18.7%), when compared to NQ (8/238; 3.4%) (P < 0.001; 183 
Table 2). Similarly, the proportion of M. genitalium samples harbouring mutations associated 184 
with dual class resistance differed, with SEQ having a significantly higher (28/209, 13.4%) 185 
rate of M. genitalium with dual class resistance, when compared to samples obtained from 186 
NQ (7/238, 3.0%; Table 2) (P = 0.0001).  187 
 188 
Differences in the levels of antibiotic resistance according to gender: 189 
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Of the 176 samples from females within the study, 98 (55.7%) had MRDR mutations and 13 190 
(7.4%) women had parC mutations. Of these women, only 8 (4.5%) harboured M. genitalium 191 
that had dual class resistance (Table 2). Macrolide resistance mutations were significantly 192 
higher in men, compared to women (P = 0.03), and this was consistent between both SEQ 193 
and NQ (Table 2). There was no significant difference in the frequency of QRDR mutations 194 
in men (34/269; 12.6%; Table 2), in comparison to women (13/176; 7.4%), and this was 195 
again consistent between both SEQ and NQ. Men and women from SEQ were more likely to 196 
harbour parC or gyrA mutations (men: 28/159 17.6%, women: 11/50, 22%) when compared 197 
to men and women in NQ (men: 6/110, 3.4%, women: 2/126, 1.6%; P = 0.007). Women from 198 
SEQ were also significantly more likely than women in NQ to harbour QRDR mutations 199 
(11/50, 22% vs. 2/126, 1.6%, respectively; P < 0.0001). Overall, the lowest observed level of 200 
resistance was for QRDR among females in NQ at 1.6% (Table 1). 201 
 202 
Table 3 provides a summary of the sample types and associated levels of resistance. While 203 
sexual orientation data for men and women were not available for this study and we were 204 
unable to determine the true proportion of male samples that were from MSM; rectal samples 205 
from males likely represent MSM since this sample type are rarely, if ever, collected from 206 
heterosexual men. Urine samples within this study however likely represent a mixture of both 207 
MSM and heterosexual individuals. When comparing genitourinary samples from females to 208 
male rectal samples (a proxy for MSM), there were differences in the proportion of MRDR 209 
mutations from male rectal samples (44/58; 75.9%), compared to female genitourinary 210 
samples (93/167, 55.7%; P = 0.007) and we also observed significant differences in the levels 211 
of dual class resistance between male rectal samples (9/58, 15.5%) and female genitourinary 212 
samples (7/167, 4.2%; P = 0.03). Sample types with less than 3 specimens were not included 213 
in these comparisons. 214 
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 215 
Urine/urethral samples from males and urine/cervicovaginal samples from women harboured 216 
similar levels of macrolide (male: 177/269, 65.8%; female: 98/176, 55.7%, P = 0.1) and 217 
quinolone (male: 34/269; 12.6%; female: 13/176, 7.4%, P = 0.1) resistance; however, there 218 
was a significant difference in dual class resistance according to gender (male: 27/269. 10%; 219 
female: 8/176, 4.5%, P = 0.04). Specimen numbers for the remaining sample types were too 220 
low to make meaningful comparisons in relation to gender (Table 3).     221 
 222 
Patients sampled over time had changes in their M. genitalium antibiotic resistance 223 
profile: 224 
The results of the 50 patients sampled on multiple occasions; are summarized in Table 4. For 225 
21/50 (42%) patients, the presence of antibiotic resistant M. genitalium appeared to persist 226 
following suspected treatment of the infection. The ‘resistance profile’ of male and female 227 
urine samples did not significantly differ from one another; however male rectal samples 228 
were more likely to have a ‘persistent’ antibiotic resistant profile (P = 0.017), in keeping with 229 
our previous finding that male rectal samples harbour high levels of antibiotic resistance. For 230 
12/50 (24%) patients, the emergence of antibiotic resistant strains appeared following 231 
antibiotic treatment, which may be consistent with de novo antibiotic resistance, where 232 
baseline samples were susceptible to the antibiotic (Table 4, Post-treatment) but may also be 233 
associated with a new infection with M. genitalium with different susceptibility patterns. For 234 
example, patient 2 had no evidence of MRDR mutations prior to antibiotic treatment, while 235 
MRDR mutations were observed 22 days after treatment. Likewise, patient 10 had MRDR 236 
mutations at both pre- and post-treatment sample collection but no QRDR mutations; 237 
however, at post-treatment sample collection and S83I quinolone antibiotic resistance 238 
mutation was evident. In 28% (14/50) of patients, we observed a potential loss of antibiotic 239 
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resistance within the patient samples between the pre- and post-treatment sample collection 240 
points; however, for two of these (patient 9 and 35) there was variation in resistance over 241 
time: for both of these patients, there was a lack of MRDR mutations observed in sample 2 242 
(post-treatment), however at the time a third sample was collected MRDR mutations were 243 
again evident. It is important to note that due to the lack of clinical data this change in 244 
resistance profile may also indicate reinfection of the patient with a susceptible strain of M. 245 
genitalium. In 3/50 (6%), no change in the antibiotic resistance profiles was observed (Table 246 
4).  247 
 248 
Discussion: 249 
Antibiotic resistance in M. genitalium has become a significant problem impacting upon the 250 
successful treatment of these infections, and is epitomized by the fact that treatment failures 251 
following recommended therapies are now commonplace (25). This is compounded due to 252 
the paucity of available and effective therapies, and a lack of alternative antibiotic choices for 253 
M. genitalium. Here, we present further evidence of the high rates of macrolide and 254 
quinolone resistance and the emergence of dual class resistance in M. genitalium obtained 255 
from Queensland, Australia, that show some regional and gender differences that likely 256 
reflect differences in ethnicity and sexual orientation, which have significant implications for 257 
clinical care.  258 
 259 
Consistent with our previous pilot study conducted in Queensland [17], macrolide resistance 260 
was high, with 62% of all samples harbouring mutations associated with macrolide 261 
resistance. This level of macrolide-resistant M. genitalium is consistent with other estimates 262 
in urban centers elsewhere, including Melbourne (16), Sydney (26), New Zealand (27), Japan 263 
(24, 28, 29) and the United States (30) and these MRDR mutations have previously been 264 
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shown to be associated with elevated MIC values for macrolide antibiotics (8, 31) and 265 
clinical treatment failure with macrolides (32, 33). The level of quinolone resistance was 266 
approximately 10% across both SEQ and NQ, and is similar to recent reports from the Asia-267 
Pacific region; for example, 10.7% of cases harbouring QRDR mutations in Japan (29) and 268 
13.5% in Melbourne (20). Of note, we observed that 7.8% of M. genitalium cases harboured 269 
both MRDR and QRDR mutations consistent with resistance to both classes of antibiotics, 270 
which is also in-line with a recent study in Melbourne that reported dual class resistance was 271 
observed in 8.6% of specimens (20).  272 
 273 
These data highlight the very real challenges faced by our STI clinicians in managing M. 274 
genitalium infections and helps explain why they continue to experience treatment failures. 275 
These data also reinforce the need for using combined diagnostic resistance assays to directly 276 
inform patient treatment, rather than relying on empiric treatment. In a recent study 277 
conducted in Melbourne, Read et al. were able to achieve cure rates of >92% (compared to 278 
macrolide treatment failure rates of 39% in a previous study (19)) where patients were tested 279 
for the presence of macrolide resistant M. genitalium at the time of presentation. The patients 280 
were treated with a 7-day course of doxycycline, followed by either azithromycin or 281 
pristinamycin, depending on the results of the mutation screening. The implementation of 282 
resistance testing-guided therapy has recently been shown to have considerable potential to 283 
improve first line cure of M. genitalium infections, and based on the results of our and other 284 
studies, a method that can rapidly detect QRDR mutations of known clinical significance may 285 
also be of considerable benefit to further enhance this approach.    286 
 287 
Notwithstanding the above, our data also suggest that empiric treatment may still be viable in 288 
certain populations so long as adequate resistance surveillance data is available to directly 289 
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inform local treatment practices and guidelines. While there was no significant difference in 290 
the rates of macrolide resistance between both SEQ (65.1%) and NQ (59.2%), there was 291 
much lower quinolone resistance levels in NQ (3.4%) compared to SEQ (18.7%). Notably, 292 
quinolone resistance was only 1.6% in females in NQ, suggesting that quinolones may be 293 
highly efficacious amongst heterosexuals in NQ. Further investigations are required to 294 
explore why quinolone resistance was significantly lower among females in NQ as compared 295 
with SEQ (22%), but it is likely the differences are attributable to differences in the 296 
populations, with the NQ region also including many Indigenous populations. Differences in 297 
antibiotic susceptibility for gonococci between Indigenous and non-Indigenous Australians 298 
are well-documented, with gonococci in many Indigenous communities remaining 299 
susceptible to antibiotics such as penicillin and ciprofloxacin that are no longer recommended 300 
for use elsewhere due to widespread resistance (34). Unfortunately, we did not have access to 301 
information on patient Indigenous status to allow such comparisons to be made for M. 302 
genitalium. 303 
 304 
A further limitation of this study was the fact that we were unable to accurately correlate 305 
sexuality with our antibiotic resistance data. Studies elsewhere have shown an association 306 
between high rates of macrolide resistant M. genitalium and MSM (30, 35), with high rates of 307 
dual resistance to both macrolides and quinolones among MSM populations (30). It is, 308 
however, likely that many of the samples obtained from males within our study come from 309 
MSM, and this is supported by the fact that we observed high levels of macrolide resistance 310 
and dual class resistance in rectal samples from males (a sample type which represents 311 
MSM), when compared to genitourinary samples from females (more likely to represent 312 
heterosexual individuals) and this difference was statistically significant.  313 
 314 
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Changes in resistance among patient samples were also observed over time, which in the 315 
absence of clinical data may represent individuals prior to antibiotic treatment and then 316 
following antibiotic treatment as a test of cure, but may also represent instances of reinfection 317 
with a new strain of M. genitalium. We observed that a ‘persistent’ antimicrobial resistant 318 
genotype was found more commonly in male rectal samples, than in samples from other 319 
anatomical sites, which also supports our previous finding that male rectal samples harbor 320 
high levels of antimicrobial resistance mutations. Future studies of interest would include 321 
pairing of molecular antimicrobial resistance typing alongside clinical data, as well as the use 322 
of molecular strain typing, in order to investigate the likelihood of reinfection and generation 323 
of resistance during antimicrobial treatments.  324 
 325 
In summary, we have identified high levels of resistance to both macrolides and quinolones, 326 
as well as dual class resistance, among M. genitalium cases in Queensland. The data highlight 327 
the need for ongoing M. genitalium resistance surveillance as well as the importance of using 328 
molecular assays to tailor treatment of patients infected with M. genitalium.  329 
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Figure and table legends: 457 
Table 1. Amino acid changes in parC and gyrA genes considered to be associated with 458 
moxifloxacin failure. Amino acid position changes are reported according to the amino acid 459 
positions within the Mycoplasma genitalium G37 genome.  460 
 461 
Table 2. Levels of MRDR mutations and QRDR mutations associated with antibiotic 462 
resistance by region and gender in Queensland, Australia. The 95% confidence interval is 463 
listed in parentheses.  464 
 465 
Table 3. Antibiotic resistance according to sample site and gender. 466 
 467 
Table 4. Investigation of antibiotic resistance over time in 50 patients with multiple samples 468 
submitted to Pathology Queensland. 469 
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Table 1. Amino acid changes in parC and gyrA genes considered to be associated with moxifloxacin failure. Amino acid position changes are 
reported according to the amino acid positions within the Mycoplasma genitalium G37 genome.  
 parC amino acid changes of likely clinical 
significance1  
parC amino acid changes of uncertain 
clinical significance2 
gyrA3 amino acid changes of 
uncertain clinical significance2 
South East Queensland 
Male (n = 26) 
 
 
Female (n = 11) 
 
Ser  Ile 83 (n = 19), Asp  Asn 87 (n = 3), 
Asp  Tyr 87 (n = 3), Ser  Arg 83 (n  = 1) 
 
Ser  Ile 83 (n = 6), Asp  Asn 87 (n = 2), 
Asp  Tyr 87 (n = 1) 
 
- 
 
 
Ser  Asn 83 (n = 1), Asp  His 87 (n = 1) 
 
Gly  Cys 93 (n = 2) 
- 
Northern Queensland 
Male (n = 6) 
Female (n = 2) 
 
Ser  Ile 83 (n = 4), Asp  Tyr 87 (n = 2) 
Ser  Ile 83 (n = 1), Ser  Arg 83 (n = 1) 
 
- 
- 
 
- 
- 
1 Clinical evidence from published data suggests that these mutations may be associated with treatment failure and/or elevated minimum 
inhibitory concentrations (MIC) to antibiotics. 
2 Uncertain clinical significance of these mutations with respect to treatment failure and/or elevated MIC data from published data.  
3
 No known gyrA mutations were observed that were of known clinical significance. 
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Table 2. Levels of MRDR mutations and QRDR mutations associated with antibiotic resistance by region and gender in Queensland, Australia. 
The 95% confidence interval is listed in parentheses.  
Region Macrolide resistance mutations Quinolone resistance mutations Dual resistance mutations 
 
South East Queensland (n = 209) 
Male (n = 159) 
Female (n = 50) 
136, 65.1%    (58 – 72%) 
109, 68.5%    (61 – 76%) 
27, 54.0%      (39 – 68%) 
39, 18.7%     (13.6 – 24.6%) 
28, 17.6%     (12 – 24%) 
11, 22%       (12 - 36%)  
28, 13.4%    (9.1 – 18.8%) 
22, 13.8%    (8.9 – 20.2%) 
6, 12%         (4.5 - 24.3%) 
Northern Queensland (n = 238) 
Male (n = 110) 
Female ( n = 126) 
Undisclosed (n = 2) 
141, 59.2%    (53 – 66%) 
68, 61.8%     (52 – 71%) 
71, 56.3%     (47 – 65%) 
2, 100.0%    (16 – 100%) 
8, 3.4%        (2 – 7%) 
6, 5.5%        (2 – 12%) 
2, 1.6%         (1 – 6%) 
0, 0.0%         (0 – 84%) 
7, 3.0%       (1.2 - 6.0%) 
5, 4.5%       (1.5 - 10.3%) 
2, 1.6%       (2 - 5.6%) 
0, 0.0%       (0 - 84.2%) 
TOTAL (n = 447) 
Male (n = 269) 
Female (n = 176) 
Undisclosed (n = 2) 
277, 62.0%     (57 – 67%) 
177, 65.8%     (60 – 72%) 
98, 55.7%       (48 – 63%) 
2, 100.0%     (16 – 100%) 
47, 10.5%      (7.8 – 13.7%) 
           34, 12.6%     (8 – 16%) 
13, 7.4%        (4 – 12%) 
0, 0.0%          (0 – 84%) 
35, 7.8%     (5.5 - 10.7%) 
27, 10.0%     (6.1 - 13.4%) 
8, 4.5%        (2 - 8.8%) 
0, 0.0%         (0 - 84.2%) 
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Table 3. Antibiotic resistance according to sample site and gender. 
Sample Site and Gender Macrolide resistance mutations Quinolone resistance mutations Dual resistance mutations 
MALE URINE/URETHRAL SPECIMEN1  
 
 
131/205 (63.9%) 23/205 (11.2%) 18/205 (8.8%) 
FEMALE URINE/CERVICOVAGINAL SPECIMEN1 
 
 
93/167 (55.7%) 12/167 (7.2%) 7/167 (4.2%) 
ANAL/RECTAL SWAB 
Male (n = 58) 
Female (n = 2) 
TOTAL 
 
44/58 (75.9%) 
1/2 (50.0%) 
45/60 (75.0%) 
 
11/58 (19.0%) 
1/2 (50.0%) 
12/60 (20.0%) 
 
9/58 (15.5%) 
1/2 (50.0%) 
10/60 (16.7%) 
THROAT SWAB 
Male (n = 1) 
TOTAL 
 
0/1 (0.0%) 
0/1 (0.0%) 
 
0/1 (0.0%) 
0/1 (0.0%) 
 
0/1 (0.0%) 
0/1 (0.0%) 
UNKNOWN SITE 
Male (n = 4) 
Female (n = 8) 
TOTAL 
 
2/4 (50.0%) 
4/8 (50.0%) 
6/12 (50.0%) 
 
0/4 (0.0%) 
0/8 (0.0%) 
0/12 (0.0%) 
 
0/4 (0.0%) 
0/8 (0.0%) 
0/12 (0.0%) 
1
 Two urine samples within this study were from patients who chose not to disclose their gender. These have not been included within the table, 
but both urine samples harboured macrolide resistance mutations, but no quinolone resistance mutations. 
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Table 4. Investigation of antibiotic resistance over time in 50 patients with multiple samples submitted to Pathology Queensland. 
Retested 
patients Sample region 
Specimen site 
(gender) 
Sample 
number 
No. of days 
between sample 
collections 
Macrolide 
Resistance 
Quinolone 
Resistance1 
Dual 
Resistance 
Resistance 
profile2 
1 SEQ Urine (M) 1 7  No Yes (D87N) No Persistence  2 No Yes (D87N) No 
2 SEQ Urine (M) 1 22 No No No Post-treatment  2 Yes No No 
3 SEQ Urine (M) 1 31 Yes Yes (S83I) Yes Persistence 2 Yes Yes (S83I) Yes 
4 SEQ Urine (M) 1 127 Yes Yes (D87N) Yes Loss  2 Yes No No 
5 SEQ Urine (M) 1 58 Yes Yes (S83I) Yes Loss  2 Yes No No 
6 SEQ Urine (M) 1 35 Yes No No Post-treatment  2 Yes Yes (D87N) Yes 
7 SEQ Urine (M) 1 28 Yes No No Loss  2 No No No 
8 SEQ Rectal (M) 1 50 Yes No No Persistence 2 Yes No No 
9 
SEQ 
Urine (M) 
1 55 Yes No No Loss 2 No No No 
3 16 Yes No No 
10 SEQ Rectal (M) 1 176 Yes No No Post-treatment  2 Yes Yes (S83I) Yes 
11 SEQ Rectal (M) 1 16 Yes No No Persistence  2 Yes No No 
12 SEQ Urine (M) 1 37 No No No Post-treatment  2 Yes No No 
13 SEQ Urine (M) 1 18 Yes No No Loss  2 No No No 
14 SEQ Rectal (M) 1 149 Yes No No Loss  
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2 No No No 
15 SEQ Urine (M) 1 35 Yes No No Persistence  2 Yes No No 
16 SEQ Rectal (M) 1 29 Yes No No Persistence  2 Yes No No 
17 SEQ Urine (M) 1 48 Yes No No Post-treatment dual resistance 2 Yes Yes (S83I) Yes 
18 SEQ Urine (M) 1 25 Yes No No Loss  2 No No No 
19 SEQ Urine (M) 1 36 Yes Yes (S83I) Yes Loss 2 Yes No No 
20 SEQ Urine (M) 1 29 No No No Post-treatment  2 Yes No No 
21 SEQ Urine (M) 1 19 No No No Post-treatment  2 Yes No No 
22 SEQ Urine (M) 1 25 No No No No change 2 No No No 
23 SEQ Urine (M) 1 37 No No No No change 2 No No No 
24 SEQ Urine (M) 1 113 Yes Yes (S83I) Yes Loss  2 Yes No No 
25 SEQ Cervix (F) 1 31 Yes No No Persistence  2 Yes No No 
26 SEQ Urine (M) 1 169 Yes No No Persistence  2 Yes No No 
27 SEQ Rectal (M) 1 36 Yes No No Persistence  2 Yes No No 
28 SEQ Unspecified site (M) 1 43 Yes No No Loss  2 No No No 
29 SEQ Vaginal (F) 1 40 Yes No No Loss  2 No No No 
30 NQ Vaginal (F) 1 127 Yes No No Persistence  2 Yes No No 
31 NQ Urine (M) 1 80 Yes No No Loss  
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2 No No No 
32 NQ Rectal (M) 1 98 No No No Post-treatment  2 Yes No No 
33 NQ Urine (F) 1 124 No No No No change 2 No No No 
34 
NQ 
Urine (F) 
1 34 Yes No No Persistence  2 Yes No No 
3 50 Yes No No 
35 
NQ 
Urine (M) 
1 54 Yes No No Loss 2 No No No 
3 43 Yes No No 
36 NQ Vaginal (F) 1 103 No No No Post-treatment  2 Yes No No 
37 NQ Rectal (M) 1 82 Yes No No Persistence 2 Yes No No 
38 NQ Urine (M) 1 113 Yes No No Persistence 2 Yes No No 
39 NQ Urine (M) 1 26 No No No Post-treatment  2 Yes No No 
40 NQ Urine (unk3) 1 37 Yes No No Loss  2 No No No 
41 NQ Urine (M) 1 36 Yes No No Persistence 2 Yes No No 
42 NQ Urine (M) 1 9 Yes No No Persistence 2 Yes No No 
43 NQ Rectal (M) 1 28 Yes Yes (D87N) Yes Persistence  2 Yes Yes (D87N) Yes 
44 NQ Urine (M) 1 41 Yes No No Persistence 2 Yes No No 
45 NQ Rectal (M) 1 45 No No No Post-treatment 2 Yes No No 
46 NQ Urine (F) 1 42 No No No Post-treatment 2 Yes No No 
47 NQ Rectal (M) 1 54 Yes No No Persistence 
 o
n
 January 6, 2019 by guest
http://jcm.asm.org/
D
ow
nloaded from
 
2 Yes No No 
3 43 Yes No No 
48 NQ Urine (unk3) 1 39 Yes No No Persistence 2 Yes No No 
49 NQ Urine (M) 1 15 Yes No No Persistence 2 Yes No No 
50 NQ Rectal (M) 1 29 Yes No No Persistence 2 Yes No No 
1
 Quinolone mutations within the parC topoisomerase gene, as per M. genitalium G37 amino acid numbering.  
2 Changes in resistance profiles from patient samples:  
‘Persistence’ of resistance: indicates mutation persistently detected but in the absence of accompanying clinical data may reflect treatment failure, 
lack of treatment or reinfection  
‘Post-treatment’ resistance: indicates the appearance of post-treatment (de novo) resistance mutations when the baseline sample was wildtype (no 
resistance mutation);  
‘Loss’ of detectable resistance: indicates that baseline resistance and follow-up sample was wildtype. In the absence of clinical data this may reflect 
reinfection with susceptible strain or inability of assay to detect resistance mutation in a low load MRDR infection;  
‘No change’ in resistance status: no changes observed in antibiotic resistance mutations;  
 
3 These patients chose not to disclose their gender.  
 
 o
n
 January 6, 2019 by guest
http://jcm.asm.org/
D
ow
nloaded from
 
